Original ArticlesOctreotide negates the benefit of GALANTIDE (cas 138579-66-5) when used in the treatment of caerulein-induced acute pancreatitis in mice
-
Add time:09/03/2019 Source:sciencedirect.com
BackgroundWe have previously shown that GALANTIDE (cas 138579-66-5), a non-specific galanin receptor antagonist, ameliorates acute pancreatitis (AP) induced in mice. Octreotide, a somatostatin analogue, has been used in the treatment of AP with inconsistent outcomes. This study set out to compare the efficacy of a combined treatment of galantide and octreotide with the efficacy of each agent individually in experimental AP.
We also recommend Trading Suppliers and Manufacturers of GALANTIDE (cas 138579-66-5). Pls Click Website Link as below: cas 138579-66-5 suppliers
Prev:Advances in the synthesis and recent therapeutic applications of 1,2,4-thiadiazole heterocycles
Next:The efficacy of combining feG and GALANTIDE (cas 138579-66-5) in mild caerulein-induced acute pancreatitis in mice) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Regular ArticleGALANTIDE (cas 138579-66-5) IMPROVES SOCIAL MEMORY IN RATS☆09/07/2019
- Short communicationGALANTIDE (cas 138579-66-5) stimulates sexual behavior in male rats09/06/2019
- Short communicationGALANTIDE (cas 138579-66-5) distinguishes putative subtypes of galanin receptors in mudpuppy parasympathetic neurons09/05/2019
- The efficacy of combining feG and GALANTIDE (cas 138579-66-5) in mild caerulein-induced acute pancreatitis in mice09/04/2019
